Pipeline

Innovative Pipelines

As a pioneer and leading player in the development of innovative drugs located in China, Chipscreen Biosciences focuses on satisfying unmet clinical demand by developing first-in-class drugs based on unique molecular entities that are clinically effective for major diseases and enjoy global patent protection. Our efforts to date have yielded:

  • 2

    Approved Drug (4 indications)

  • 6

    Products In The Clinical Development Stage

  • 20+

    New Molecular Entities In The Preclinical Stage

Pipeline Chidamide Chiglitazar Chiauranib CS23546 CS231295 CS32582 Other Products Under Development

微芯生物重点布局肿瘤与代谢两大领域,持续关注神经退行性疾病、自身免疫性疾病等重大未满足临床需求,深化管线差异化布局,持续提升全球患者获益。

 

Our Partners

Research Partners

  • 中国军事医学科学院
  • 复旦大学药物基因组学研究中心
  • 中国医学科学院/协和医科大学
  • 四川大学华西医学院国家中药GLP安全评价中心
  • 第二军医大学新药评价中心
  • 香港大学
  • 中国人民解放军三〇一医院
  • 中国医学科学院肿瘤医院
  • 北京大学人民医院

Business Partners

  • 信达生物
  • HUYA Bioscience International
  • 华上生技医药股份有限公司
  • 康宁杰瑞
  • 思路迪
  • 百济神州
  • 康方生物